% | $
Quotes you view appear here for quick access.

Galena Biopharma, Inc. Message Board

  • n9zro n9zro Jun 3, 2013 12:13 PM Flag


    Galena Biopharma provides product pipeline update at ASCO annual meeting
    Galena Biopharma announced two publications at the American Society of Clinical Oncologists, or ASCO, Annual Meeting taking place May 31-June 4 in Chicago, Illinois. The company also provided an update on the ongoing Folate Binding Protein Phase 1/2 clinical trial. The study concluded that in completed phase 1/2 trials of NeuVax, patients who exhibit robust in vitro IR have lower recurrence rates. This finding suggests that nelipepimut-specific CTL clonal expansion is a valid biomarker for CR in patients treated with NeuVax. In the SN-33 trial, the 60-month Landmark Analysis demonstrated a 5.6% recurrence rate with NeuVax vs. a 25.9% recurrence rate in the control arm--a recurrence reduction of 78.4%.

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.73+0.03(+1.76%)May 27 4:00 PMEDT